B of A Securities Downgrades LianBio to Underperform, Lowers Price Target to $3
LianBio Analyst Ratings
Jefferies Downgrades LianBio to Hold, Lowers Price Target to $4
LianBio Analyst Ratings
BofA Securities Adjusts LianBio Price Target to $5 From $6, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: LianBio Sponsored ADR (LIAN), Centene (CNC) and Bioxcel Therapeutics (BTAI)
Raymond James Maintains Outperform on LianBio, Lowers Price Target to $9
LianBio Analyst Ratings
Raymond James Sticks to Its Buy Rating for LianBio Sponsored ADR (LIAN)
LianBio Sponsored ADR (LIAN) Gets a Buy From Jefferies